Journal
EPILEPSIA
Volume 51, Issue 2, Pages 297-300Publisher
WILEY
DOI: 10.1111/j.1528-1167.2009.02269.x
Keywords
Carbamazepine; Stevens-Johnson syndrome; HILA class I; HLA-B*5901; Cutaneous adverse drug reactions
Categories
Funding
- Health and Labour Sciences Research Grants for Research on Human Genome [H18-002, 19A-6]
- Ministry of Health. Labor and Welfare [16590859, 17591133, 19591234]
- Grants-in-Aid for Scientific Research [16590859, 17591133, 19591234] Funding Source: KAKEN
Ask authors/readers for more resources
Carbamazepine (CBZ) is frequently used for treating epilepsy, but this drug causes cutaneous adverse drug reactions (cADRs) that may range from mild to severe. It is reported recently that the human leukocyte antigen HLA-B*1502 is associated with Stevens-Johnson syndrome (SJS) induced by CBZ in Han Chinese. We examined HLA class I in 15 Japanese patients who fulfilled the diagnostic criteria for CBZ-induced cADRs (mild in 10 and severe = SJS in 5). HLA-B*1518, HLA-B*5901 and HLA-C*0704 alleles showed higher relative risks (above 10.0) for severe cADRs. The haplotype (HLA-A*2402-B*5901-C*0102) had high relative risk (16.09) for severe cADRs. In patients with severe cADRs, frequencies of HLA-A*1101, HLA-A*3303, HLA-B*1501, HLA-B*4403, HLA-B*5101, HLA-B*5201, HLA-C*0702, and HLA-C*1202 alleles are relatively lower than in the Japanese population. These data may suggest that HLA-B*5901 is one of the candidate markers for CBZ-induced SJS in Japanese.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available